TheraBond

TheraBond is a medical technology company that specializes in advanced wound care products, aiming to improve healing outcomes for patients with chronic and acute wounds through innovative solutions. TheraBond, developed by Alliqua BioMedical, focuses on advanced wound care solutions. In September 2017, Argentum Medical LLC acquired TheraBond from Alliqua BioMedical, but specific financial terms were not disclosed. The company was founded by Nadeem Alikhan, who has a history of innovation in the medical field.

TheraBond is headquartered in the United States. Alliqua BioMedical, Inc. specializes in advanced wound care solutions, focusing on the enhancement of healing for both chronic and acute wounds. Their core product offerings include TheraBond® 3D, BIOVANCE®, and MIST Therapy®, among others, which are designed to facilitate various aspects of wound management.

TheraBond® 3D, for instance, is a unique hydrogel-based solution that promotes an optimal healing environment for surgical sites and burns, while BIOVANCE® is a regenerative tissue product aimed at accelerating wound healing. The company's products are utilized by healthcare providers such as hospitals, clinics, and outpatient facilities, serving a diverse client base that includes surgeons, wound care specialists, and medical practitioners across North America and select international markets. Alliqua BioMedical, Inc. generates revenue through sales of its advanced wound care products, which are typically transacted directly with healthcare providers and institutions.

These transactions are structured as business-to-business dealings, where products are sold to hospitals and clinics that integrate them into their treatment protocols. Pricing structures for flagship products, such as TheraBond® 3D and BIOVANCE®, align with industry standards for advanced medical supplies, providing value to healthcare practitioners in need of effective wound care solutions. The company's revenue strategy also includes partnerships with distributors and wholesalers, enhancing market reach and ensuring that their products are readily accessible to end-users in various healthcare settings. TheraBond is strategically planning for future growth through the development of new products and potential expansion into international markets.

While specific upcoming products have not been detailed, the company aims to leverage innovations in wound care technology. Following its acquisition in September 2017, TheraBond is positioned to enhance its product offerings and market presence under the leadership of Argentum Medical LLC. This acquisition will likely support their initiatives to penetrate additional healthcare markets, although exact timelines for these expansions have yet to be clarified.